Newly-funded OncoGenome set to move assay technology forward
This article was originally published in Clinica
Cancer diagnosis start-up OncoGenome Sciences is bidding for the final tranche of an E12m ($15m) funding package from European venture capital companies. E12m has been agrees, with the funding coming from five investor groups. The Liege, Belgium company will use the funds to validate the clinical use of its noninvasive, genomics-based cancer tests.